MedPath

Treatment of Diabetic Foot Ulcers With Inforatio Technique to Promote Wound Healing

Not Applicable
Completed
Conditions
Wound Heal
Ulcer Foot
Ulcer Healing
Diabetic Foot Ulcer
Diabetic Foot
Interventions
Procedure: Inforatio technique
Registration Number
NCT03985306
Lead Sponsor
Zealand University Hospital
Brief Summary

This trial will examine the feasibility of conducting a definitive randomized clinical trial that tests whether inforatio technique will reduce time to healing of diabetic foot ulcers. Inforatio technique is a procedure where small punch biopsies are taken from the wound bed near the edge of the wound. With this technique, the investigators wish to initiate an acute inflammatory response that increases the generation of granulation tissue with subsequent healing by scar formation. Thus, the investigators hypothesize that inforatio technique will promote healing of diabetic foot ulcers.

Based on clinical experience, the investigators have previously detected a reduction in time to healing as an unexpected effect when multiple punch biopsies are taken from the wound bed of diabetic foot ulcers. To the knowledge of the investigators, methods similar to the inforatio technique has not previously been studied.

Detailed Description

BACKGROUND

The prevalence of diabetic foot ulcers is expected to increase considerably due to a continuously increasing prevalence of diabetes. The healing process of diabetic foot ulcers is complicated by a complex pathophysiology of the distal lower extremities and a constant exposure to bacteria and pressure. Improving healing of diabetic foot ulcers will have several benefits including higher quality of life, reduced morbidity, reduced mortality and lower socioeconomic costs. Nonetheless, there are few randomized controlled clinical trials on surgical and non-surgical treatment chronic foot ulcers and many studies on the topic have a low level of evidence.

TRIAL AIMS

The investigators aim to assess the feasibility of conducting a definitive randomized controlled trial by exploring recruitment, patient acceptability, protocol adherence and adverse effects.

The success criteria of the trial is as follows:

* Weekly recruitment rates at two patients or more.

* Time from first outpatient visit to recruitment at 21 days or less.

* Retention rate at 90-day follow-up at 50% or more

* No appearance of unacceptable adverse effects In addition, the trial aims to assess logistic concerns regarding the trial and to improve the method of inforatio application.

Based on findings from the feasibility trial, the investigators may amend the design of the definitive trial.

RECRUITMENT

Patients are eligibility-screened and identified by the primary investigator and wound care staff when patients visit wound outpatient clinics at the recruiting facilities.

INCLUSION AND FOLLOW-UP

Eligible patients are included if they give their oral and written consent to participate. The baseline trial visit take place on the day that patients give their consent to participate.

The trial comprises a 90-day clinical follow-up. Follow-up visits will be at 10, 21, 42 and 90 days after baseline (give or take 3 days). Wounds are assessed at each trial visit. The inforatio technique is applied at baseline and again at the 21-follow-up day if the wound still has a diameter larger than four mms. Participants unable to attend at the precise dates for midtrial follow-up will be eligible for follow-up three days before or after the intended date. The participants who cannot attend during this window will skip the follow-up day in concern. If the participants miss the second intervention at the 21-day follow-up, they are excluded. For the 90-day follow-up, participants are recalled two times by the primary investigator within two weeks before being excluded.

Participants exit from the trial if following occurs during follow-up:

* they undergo surgeries described in the exclusion criteria

* they get acute signs of infection, gangrene or osteomyelitis in their foot in concern

* their tendons, joints or bone become exposed in the wound bed

* they develop an acute phase of charcot arthropathy in their foot in concern

* they get admitted for reasons related to their foot ulcer

* they die or emigrate

The trial is stopped if the intervention shows an unintended effect or potential harm.

TRIAL STANDARD TREATMENT

The participants receive a trial standard treatment at every trial visit. The treatment is conducted by the primary investigator in cooperation with wound care nurses and podiatrists. The standard treatment is defined based on Danish National guidelines, local guidelines of the recruiting facilities and guidelines of the National Institute for Health and Care Excellence.

The treatment is based on a flowchart that individualizes treatment based on clinical wound characteristics.

INFORATIO TECHNIQUE

The technique is described in the Arms and Interventions section.

TRIAL MEASURES

Wound assessment: Wounds are assessed at every trial visit. To monitor the ulcer area during follow-up, the investigators will analyze digital photos of the ulcer by using Image J which is a wound planimetry software. The depth of the ulcers are measured with sterile wound probes and reported by intervals of 5 millimeters. Undermining will be assessed with the same method as for depth and in intervals of 5 millimeters.

Microbial samples: At both stages of inforatio application, three punch biopsies are sent for cultivation to analyze bacterial species, bacterial load and resistance patterns of the bacteria.

Patient and staff interviews: described in the Outcome Measures section

STATISTICAL ANALYSIS

With descriptive statistics participants' demographics, the quantitative success criteria, the quantitative outcome measures and time to healing will be reported. Clinical healing is defined by intact epithelia.

The investigators will use statistical software SPSS version 21.0 (IBM Corp., Armonk, New York).

SAMPLE SIZE CONSIDERATION

Because effectiveness is not evaluated, a formal power calculation is not considered necessary for the objectives of a feasibility trial.

To minimize the number of patients that are exposed to a new intervention meanwhile keeping a level of precision for the variance estimate, the rule of thumb by Julious et al will be used for determination of the trial sample size. Thus, 12 participants will be included in the trial. Julious et al argues that a sample size of 12 per group gives a sufficient precision of the mean and variance estimates. Other studies report rules of thumbs with larger sample size to gain sufficient power for a pilot or feasibility trial.

ETHICAL CONSIDERATIONS AND RISK ASSESSMENT OF SIDE EFFECTS

The procedure of the intervention is small with an expectedly small risk of harm outcomes. The punch biopsies from the inforatio technique is relatively shallow therefore it is not expected that it will penetrate important anatomical structures or expose bone.

The primary investigator's clinical assessment, patient preference and patient tolerance is taken into consideration before inforatio technique is applied. Minimal discomfort is expected for the participants when they receive the inforatio technique treatment. Previous applications by the investigators showed that patients reported no or little pain during application.

The inforatio technique treatment has previously shown potential to improve healing thus participants may gain an improvement in healing of their foot ulcers.

If this trial shows that a definitive randomised clinical trial will be feasible, the investigators will examine the effect of inforatio technique through a larger randomised clinical trial. If the inforatio technique shows significant positive effect on time to healing it would become of great importance for future diabetic foot ulcer patients. The inforatio technique would become an addition to available therapeutic options. The technique is simple and only requires a punch biopsy tool. Nurses and general practitioners can be potential applicants that apply the treatment at clinics close to patient habitats making visits for wound treatment more convenient for the patients. If there is a significant positive effect on healing, it is expected that it will result in reduction of hospital admissions and less surgical interventions including amputations.

This project may contribute to more focus on treatment of patients with diabetic foot ulcers - a field of research that still needs studies to enable evidence-based treatment.

Inspectors from The National Committee of Health Research Ethics will have the authorization to quality control the trial.

COMPETING INTERESTS

The trial investigators declare that they have no competing interests.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
12
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Feasibility trial groupInforatio techniqueEvery trial patient will receive the intervention (the inforatio technique) that is intended for the definitive randomized clinical trial.
Primary Outcome Measures
NameTimeMethod
Refusal ratesThe first 2 months of the trial (untill the last patient has been recruited)

Descriptive statistics of number and rate of eligible patients that refuse trial participation.

Eligibility ratesThe first 2 months of the trial (untill the last patient has been recruited)

Descriptive statistics of number and rate of eligible patients during the period of recruitment

Time from identification to inclusionThe first 2 months of the trial (untill the last patient has been recruited)

Descriptive statistics of average time from eligible patients are identified to they are included in the trial (baseline trial visit)

Qualitative assessment of patient acceptability10 months

Assessed by interviews with participants.

Qualitative assessment of the extent of qualitative patient measures10 months

The investigators assess whether the qualitative patient measures are either too extensive or insufficient. Thus, estimating necessary changes to make the qualitative measurements feasible to include in the future definitive trial.

Rates of wound treatments at trial visits that deviate from the trial standard treatment definition10 months

Standard treatments received by each patient at the follow-up visits are recorded and it is assessed whether the standard care received corresponds to the definition of the trial standard treatment.

Time to healing of the foot ulcers10 months

The investigators will report mean and variance of time to healing

Patient-reported experience of trial participation and the inforatio technique10 months

The investigators will interview the patient about their experience of trial participation and of the inforatio technique.

Qualitative assessment of unexpected factors that must cause exclusion10 months

Qualitatively assessed by the primary investigator

Rate of unexpected exclusion10 months

Descriptive statistics of number and rate of patients that are excluded due to reasons not already covered by the trial definition of exclusion criteria.

Retention rates10 months

To investigate protocol adherence, the number and rate of participants that adhere to follow-up will be reported.

Patient-reported potential side effects10 months

A qualitatively assessment of harms and unexpected effects by interviewing participants about potential side effects that they experience.

Qualitative assessment of logistics issues regarding outpatient clinic visits10 months

The investigators qualitatively assesses logistic circumstances that may be optimized.The assessment includes whether dates of follow-up visits fit the routines at the outpatient clinics.

Time to healing of punch biopsy scars10 months

The time to healing will be reported to estimate if and when observer blinding may be possible.

Number of missed trial follow-up visits10 months

To investigate protocol adherence, the number of missed trial visits will be reported for each participant.

Drop-out rates10 months

To investigate protocol adherence, the number and rate of participants that choose to drop out during follow-up will be reported.

Rate of eligible patients that accept participationAt baseline, each follow-up visit and when patients drop out.

A quantitative investigation of patient acceptability.

Observed harms and unexpected effects10 months

Observed harms and unexpected effects observed by the investigators and staff will be reported.

Qualitative assessment of wound care treatments received between trial visits and the deviations from the trial definition of standard treatment.10 months

The investigators assess the heterogeneity of treatment during follow-up by recording the number of hospital visits between the trial follow-up visits and the treatments and assessments received at these hospital visits.

Qualitative assessment of the method of wound assessment.10 months

The investigators assess complications related to the method wound bed area and the depth. The aim is to optimize wound assessment for the future definitive trial.

Qualitative assessment of the feasibility of culturing 3 biopsies from each round of inforatio technique applications for a future definitive trial.10 months

The investigators assess whether the included centers have the capacity to culture three biopsies two times from each patient.

Qualitative assessment of the inforatio technique5 months. At baseline application and at the 21-day applications.

The method of inforatio technique application will be qualitatively assessed by the applicant. The applicant will report any issues or complications regarding the inforatio technique definition.

Staff acceptability10 months

Assessed qualitatively by interviews with the staff at the outpatient clinics (wound care nurses and podiatrists)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Herlev University Hospital, Department of Orthopaedic Surgery

🇩🇰

Herlev, Denmark

Zealand University Hospital, Department of Orthopaedic Surgery

🇩🇰

Køge, Denmark

© Copyright 2025. All Rights Reserved by MedPath